Skip to main content
Quest Diagnostics

Genetic Findings in a Cohort of Over 1,000 Patients with Suspected Monogenic Lipid Disorders

SIGU 2025

Societa Italiana di Genetica Umana XXVIII SIGU National Conference

Rimini, Italy, Sep 23-25,  2025

Poster presentation: Genetic Findings in a Cohort of Over 1,000 Patients with Suspected Monogenic Lipid Disorders

Authors: Costantini A, Hathaway J, Huusko J, Ahonen S, Tommiska J, Gall K, Sluyters A,  Scocchia A, Liaquat K, Djupsjöbacka J, Muona M, Saarinen I, Seppälä E, Kangas-Kontio T, LKoskinen L, Salmenperä P, Myllykangas S, Koskenvuo J

Medical Specialty: Cardiology, Endocrinology, Cardiovascular disease, Genetics

Disclaimer:  One or more of the authors of this publication were employed at the time by BluePrint Genetics, a subsidiary of Quest Diagnostics.

Related content

Audio Podcast
Actions From Insight: GLP-1 Receptor Antagonists and Building Healthy Habits
On-Demand Webinar
Utilizing Lipoprotein(a) in Cardiovascular Risk Assessment
Audio Podcast
Instant Insight: Kidney Profile and Cystatin C
Test FAQ
Insulin Intact LC MS MS
Publication
A Primer on Regulation of Laboratory-Developed Testing Procedures: A Points to Consider Statement of the American College of Medical Genetics and Genomics (ACMG)

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2025 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.